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Effectiveness of LVAD in Ambulatory HF
transplant within 1 year were excluded from the primary endpoint analysis. *12 optimal medical management (OMM) patients missing 6-min walk distance data were excluded from the primary endpoint analysis. †8 left ventricular assist device (LVAD) patients missing 6MWD data were excluded from the primary endpoint analysis. ‡Includes 1 elective and 2 urgent transplants. Values are n (%) of patients responding to question.
QoL ¼ quality of life; other abbreviations as in Table 1 . Patient questionnaires at baseline demonstrated that more LVAD patients reported that they were not satisfied or only slightly satisfied with their quality of (14) Patient is not sick enough 11 (11) Other (e.g., substance abuse, financial, compliance concerns) 9 (9) Values are n (%) of patients who completed questionnaire. *Patients may select >1 response. †Surgical reasons provided: history of anticardiolipin antibody and splenectomy (high risk of clotting); lack of social support and noncompliance; medical nonadherence; interstitial fibrosis; obesity; liver cirrhosis; severe chronic obstructive pulmonary disease; concern regarding postoperative recovery; large sacral decubitus ulcer; recent stroke. Tables 1 and 2 . 
Abbreviations as in
Values are n (%). Odds ratio is calculated (95% confidence interval) as LVAD versus OMM. *Excluded OMM patients: 9 withdrawn, 12 missing 6MWD. †Excluded LVAD patients: 3 withdrawn, 8 missing 6MWD, 1 elective heart transplant. ‡Including 1 total artificial heart.
NA ¼ not applicable; other abbreviations as in Table 1 .
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life on baseline medical therapy (79%) compared with those who remained on OMM (48%) ( Table 2) .
Significantly more LVAD patients at baseline also reported a perception that they were going to live <1 year (53% vs. 9%). The main patient reasons given for choosing OMM instead of LVAD include not wanting major device surgery, not wanting to depend on a machine, and not feeling sick enough ( Table 3) .
For patients who agreed to LVAD therapy, the main reasons given were anticipated improvement in survival and improvements in quality of life and HF symptoms. Intention-to-treat survival was not significantly different between OMM and LVAD patients. HR was calculated for OMM versus LVAD. *One patient received a total artificial heart and was censored alive, then withdrawn from the study. Abbreviations as in Figures 1 and 2 . Abbreviations as in Figure 1 . Table 5) .
ADVERSE EVENTS. AEs were more frequent in LVAD patients than in OMM patients ( Table 6) . Bleeding was the primary driver of LVAD AEs; together, surgical and nonsurgical bleeding accounted for 65% of LVAD events. Worsening HF, which accounted for 82% of OMM events, was the primary driver of OMM AEs.
Pump thrombus occurred in 6 LVAD patients, Values are n/N (%). Odds ratio is calculated (95% confidence interval) LVAD versus OMN. *Includes patients in bottom 3 quartiles of baseline VAS (<68). †Includes patients with baseline PHQ-9 $5 (mild or more severe), thus excluding those with no or minimal depression.
HRQoL ¼ health-related quality of life; other abbreviations as in Table 1 . Abbreviations as in Figure 1 . Elective procedure 10 (6) 22 (7) Comorbidity management 13 (8) 16 ( Values are n (%) of rehospitalizations. *Most frequent OMM rehospitalization reason was worsening HF, which included 9 delayed HMII and 1 total artificial heart implantation. †Most frequent LVAD rehospitalization reason was bleeding. ‡In-cludes thoracentesis, depression, fever, failure to thrive, peripherally inserted central catheter line pulled out, dyspnea, and cellulitis.
Abbreviations as in Table 1 . Survival, changes in functional capacity, health-related quality of life (HRQol), and depression favor LVAD therapy, but the adverse event rate favors OMM. *Includes patients with baseline VAS <68 (lowest 3 quartiles). †Includes patients with baseline PHQ-9 scores >4 (mild or worse depression severity). LCL ¼ lower confidence limit; OR ¼ odds ratio; UCL ¼ upper confidence limit; other abbreviations as in Figures 1, 2,   6 , and 7. Values are median (quartile1-3) or n (%).
Abbreviations as in Table 1 .
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